Platinum (Pt)-based anticancer drugs, exemplified by cisplatin, are key components in combination chemotherapy. However, their effective use is hindered by toxicity and emergence of drug resistance. They bind to DNA and mainly form the Pt-GG diadduct, subsequently leading to apoptosis to mediate cell death. On the other hand, the Pt drug -proteins and -metabolites interactions, which involve the reaction between Pt and sulfur sites located in protein side chains and important bionucleophiles (e.g., glutathione), are responsible for the toxicity and drug resistance problem. Therefore, carefully designed coordinating ligands may provide the means of fine tuning the electronic environment around the core Pt atom and allow the resulting Pt compounds to bind with the DNA in a different manner. This may produce alternative cell death mechanisms in cancer cells, thereby circumventing Pt resistance. This article reviewed the recent development in monofunctional Pt complexes and their prospects in becoming a new generation of anticancer drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0929867323666160311114509 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Theoretical investigation of structure and electronic properties in Cisplatin-citrate complexes.
J Comput Chem
January 2025
Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Cisplatin (CDDP) is an effective Platinum (Pt) based anticancer drug used in chemotherapy. However, its effectiveness is limited due to its instability in solvents, along with the side effects it causes due to DNA damage. Nanoparticles (NPs) were developed in vitro to address these issues by loading CDDP into various types of NPs, including metal, lipid, and biological NPs.
View Article and Find Full Text PDFNovel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm.
Biomaterials
March 2025
Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA. Electronic address:
Article Synopsis
- Induction of reactive oxygen species (ROS) is crucial for cancer treatment, but current methods are often ineffective due to low ROS production.
- Researchers have developed a new platinum-based drug called "carrier-platin," which uses nanoparticles to significantly boost ROS production in cancer cells, leading to rapid cell death (within 30 minutes).
- Unlike traditional platinum drugs that target DNA, carrier-platin kills cancer cells through a unique mechanism that bypasses DNA damage, showing enhanced effectiveness against a wide range of cancers, including those resistant to other treatments, with minimal side effects.
Recent Advances on Pt-Based Compounds for Theranostic Applications.
Molecules
July 2024
Department of Chemistry, Maynooth University, W23 F2H6 Maynooth, Ireland.
Since the discovery of cisplatin's antitumoral activity and its approval as an anticancer drug, significant efforts have been made to enhance its physiological stability and anticancer efficacy and to reduce its side effects. With the rapid development of targeted and personalized therapies, and the promising theranostic approach, platinum drugs have found new opportunities in more sophisticated systems. Theranostic agents combine diagnostic and therapeutic moieties in one scaffold, enabling simultaneous disease monitoring, therapy delivery, response tracking, and treatment efficacy evaluation.
View Article and Find Full Text PDFPicoplatin binding to proteins: X-ray structures and mass spectrometry data on the adducts with lysozyme and ribonuclease A.
Dalton Trans
May 2024
Department of Chemical Sciences, University of Naples Federico II, Complesso universitario di Monte Sant'Angelo, via Cinthia, 21, 80126, Naples, Italy.
The reactivity of the anticancer drug picoplatin (-amminedichlorido(2-methylpyridine)platinum(II) complex) with the model proteins hen egg white lysozyme (HEWL) and bovine pancreatic ribonuclease (RNase A) was investigated by electrospray ionisation mass spectrometry (ESI MS) and X-ray crystallography. The data were compared with those previously obtained for the adducts of these proteins with cisplatin, carboplatin and oxaliplatin under the same experimental conditions. ESI-MS data show binding of Pt to both proteins, with fragments retaining the 2-methylpyridine ligand and, possibly, a chloride ion.
View Article and Find Full Text PDFJoint forces of mass spectrometric techniques (ICP-MS and MALDI-TOF-MS) and fluorescence spectrometry in the study of platinum-based cytostatic drugs interactions with metallothionein MT2 and MT3.
Talanta
July 2024
Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1665/1, CZ-61300, Brno, Czech Republic. Electronic address:
Herby, the interaction of metallothioneins with commonly used Pt-based anticancer drugs - cisplatin, carboplatin, and oxaliplatin - was investigated using the combined power of elemental (i.e. LA-ICP-MS, CE-ICP-MS) and molecular (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!